Video

Dave Dixon from Virginia Commonwealth University: Anti-Obesity Agents Provide Some Hope for Patients

Author(s):

The US Food and Drug Administration recently approved some new tools in the fight against obesity. While they provide some help for patients looking to lose weight there are also side effects which doctors and patients patients to consider.

%jwplayer%

The US Food and Drug Administration recently approved some new tools in the fight against obesity. While they provide some help for patients looking to lose weight there are also side effects which doctors and patients patients to consider.

Dave L. Dixon, PharmD, from Virginia Commonwealth University discussed these new agents and what they can mean to patient care during the American College of Cardiology's 65th Annual Scientific Session and Expo in Chicago. While endocrinologists may be more familiar with the new options Dixon said they can also be a factor in treating cardiovascular disease as well. 

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.